TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,942,443 | -41.8% | 552,846 | 0.0% | 1.32% | -22.9% |
| Q2 2023 | $8,491,715 | +20.4% | 552,846 | +76.3% | 1.71% | -6.7% |
| Q1 2023 | $7,053,809 | +19.1% | 313,642 | +11.3% | 1.83% | +19.3% |
| Q4 2022 | $5,924,382 | -13.0% | 281,711 | +1.9% | 1.54% | -4.7% |
| Q3 2022 | $6,812,000 | +1.1% | 276,460 | -0.5% | 1.61% | -13.8% |
| Q2 2022 | $6,735,000 | -6.0% | 277,950 | 0.0% | 1.87% | -2.7% |
| Q1 2022 | $7,163,000 | -19.8% | 277,950 | -3.5% | 1.92% | +18.0% |
| Q4 2021 | $8,936,000 | +20.2% | 287,893 | -6.1% | 1.63% | +41.3% |
| Q3 2021 | $7,433,000 | – | 306,515 | – | 1.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |